Finally, MIA-604 and MIA-690 (GH-RH antagonists) downregulate cancer markers (e.g., mitogen-activated protein kinase 1 and Jun) [109], and MSH exerts anti-inflammatory effects via the activation of NF-κB in glioma cells [124]. Here, GHRH is linked to cancer.